These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8671110)

  • 1. Doing randomized controlled trials in a developing country: some practical realities.
    Glasgow NJ; Murdoch JC; Baynouna L; al Sabosy MM; al Jabiri ON; Harron DW
    Fam Pract; 1996 Feb; 13(1):98-103. PubMed ID: 8671110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan--a new antihypertensive.
    Drug Ther Bull; 1995 Oct; 33(10):73-4. PubMed ID: 7493558
    [No Abstract]   [Full Text] [Related]  

  • 3. Losartan for hypertension.
    Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
    [No Abstract]   [Full Text] [Related]  

  • 4. Losartan and angina pectoris.
    Ahmad S
    Tex Heart Inst J; 1995; 22(4):347-8. PubMed ID: 8605440
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible ageusia associated with losartan.
    Schlienger RG; Saxer M; Haefeli WE
    Lancet; 1996 Feb; 347(8999):471-2. PubMed ID: 8618505
    [No Abstract]   [Full Text] [Related]  

  • 6. [Angiotensin II receptor antagonists. Clinical relevance].
    Scholze J
    Internist (Berl); 1996 Jun; 37(6):636-42. PubMed ID: 8767999
    [No Abstract]   [Full Text] [Related]  

  • 7. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 8. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
    Lacourcière Y; Lefebvre J; Nakhle G; Faison EP; Snavely DB; Nelson EB
    J Hypertens Suppl; 1994 Jul; 12(2):S49-53. PubMed ID: 7965266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T; Yoshinaga K
    Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis.
    Holm EA; Randløv A; Strandgaard S
    Blood Press; 1996 Nov; 5(6):360-2. PubMed ID: 8973754
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
    Dahlöf B; Keller SE; Makris L; Goldberg AI; Sweet CS; Lim NY
    Am J Hypertens; 1995 Jun; 8(6):578-83. PubMed ID: 7662242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
    Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan.
    Hansson L
    Blood Press Suppl; 1997; 1():52-5. PubMed ID: 9285110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin II receptor antagonists].
    Bornkessel B
    Med Monatsschr Pharm; 1995 Jun; 18(6):148-51. PubMed ID: 7609710
    [No Abstract]   [Full Text] [Related]  

  • 17. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
    Goa KL; Wagstaff AJ
    Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan in heart failure: preclinical experiences and initial clinical outcomes.
    Sweet CS; Rucinska EJ
    Eur Heart J; 1994 Dec; 15 Suppl D():139-44. PubMed ID: 7713103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.